Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases

Retrieved on: 
Wednesday, September 6, 2023
Obesity, NASH, Half-life, PALO, Type 1 diabetes, Research, FGF21, AAV, UAB, RESEARCH, Fibrosis, Molecular biology, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Fibroblast growth factor, PARK, Liver, Tramontane, Entrepreneurship, DSM-IV codes, Therapy, Disease, Safety, Conditional sentence, Pharmaceutical industry, Vaccine, Biochemistry, Kriyā

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it has acquired Tramontane Therapeutics, Inc. ("Tramontane"). Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.

Key Points: 
  • Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases.
  • Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.
  • "The addition of Tramontane’s FGF21 program strategically aligns with our Metabolic Disease portfolio which also includes a one-time gene therapy candidate for insulin-dependent diabetes."
  • I believe that a one-time gene therapy would be a quantum leap forward in the management of this chronic disease."

Bruker Advances NMR Magnet Portfolio, Innovates in Industrial Solutions

Retrieved on: 
Monday, April 17, 2023
Biometrics, Other Health, Batteries, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hardware, Science, Consumer Electronics, Technology, Other Energy, Biotechnology, Alternative Energy, Health, Energy, Nuclear, Health Technology, Pharmacy, Hertz, Research and development, University, NMR, Deep learning, University of South Carolina, Multimedia, Toxicity, University of Warwick, ENC, Ascend, University of Birmingham, Chemical substance, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Fourier, Magnet, Drug discovery, Helium, AI, API, Conference, Safety, Lithium, Medical imaging, Fine chemical, Industrial gas, Pharmaceutical industry, Bruker, Merck

This 400 MHz innovation joins the Ascend Evo 1.0 GHz with ~65% lower liquid helium consumption over previous 1.0 GHz magnets.

Key Points: 
  • This 400 MHz innovation joins the Ascend Evo 1.0 GHz with ~65% lower liquid helium consumption over previous 1.0 GHz magnets.
  • Bruker offers helium recovery with its HelioSmart-R, a compact system to collect helium gas boil-off from magnets.
  • At ENC 2023, Bruker also introduces new industrial and pharmaceutical capabilities for the Fourier™ 80 benchtop FT-NMR platform.
  • I am excited to see what new scientific, pharma and cleantech advancements will be enabled by NMR technology.”
    To learn about Bruker at ENC, please visit: https://www.bruker.com/en/news-and-events/events/enc.html

Bruker Announces Successful Customer Installations of First Two Compact 1.0 GHz NMR Systems to Advance Structural Biology

Retrieved on: 
Friday, February 3, 2023
Stem Cells, Medical Supplies, Biotechnology, Other Health, Health, Biometrics, Other Science, Medical Devices, Research, Science, Clinical Trials, Singular, GPCR, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Molecular biology, Ascend, Intrinsically disordered proteins, Helium, ICTS, RNA, Hertz, University of Barcelona, CIC, Multimedia, RIKEN, NMR, Internally displaced person, Medical imaging, Bruker

Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.

Key Points: 
  • Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.
  • These new 1.0 GHz NMR magnets also have significantly reduced footprint, weight, and ceiling height requirements and fit into most single-story laboratories.
  • Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "We are excited to announce the remarkably rapid delivery and customer acceptance of two 1.0 GHz NMR systems.
  • These low-maintenance, compact NMRs with lower helium consumption can bring the power of GHz NMR to many more laboratories.”

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023
Infection, NSCLC, Large-cell lung carcinoma, Secondary research, Pneumonia, Survival rate, Centre for Genomic Regulation, Union, Toxicity, Respiratory tract, Nature Biotechnology, Lluch, H2020, IRB, European Research Council, Lung cancer, Public health, Microbiology, Biotechnology, Biofilm, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, VAP, CRG, Research, Pseudomonas aeruginosa, Lung, Bacteria, Degenerative disease, Immune system, Survival, Patient, Engineering, Mouse, Mortality, European Innovation Council, Synthetic biology, Catalonia, Ventilator-associated pneumonia, Asthma, Enzyme, Inflammation, Doctor of Philosophy, Institute for Research in Biomedicine, Pharmaceutical industry, Vaccine, Science

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.

Bruker Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Retrieved on: 
Monday, August 22, 2022
Software, Research, General Health, Pharmaceutical, Hardware, Medical Devices, Technology, Health Technology, Science, Biotechnology, Neurology, Health, EPR, Technology, 3D, Biotop, Research, CIC, University of Barcelona, University of Lille Nord de France, Organic acid, MAS, Neurodegeneration, Cell biology, HTS, Hertz, HCN, University, Helium, Cancer, Biochemistry, IDP, Department, Intrinsically disordered proteins, Microscopy, CNRS, University of Lille, NMR, Carbohydrate, Harvard Medical School, Solution, Arthanari, Precision medicine, Metalloprotein, Prion, Multimedia, Membrane protein, Crystallography, Proteomics, 14N, Magic angle spinning, Kelvin, Associate, Dana–Farber Cancer Institute, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Pharmacology, Internally displaced person, Lyon, Conference, Phosphorylation, Ascend, Life, Medical imaging, Bruker

The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.

Key Points: 
  • The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.
  • It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances.
  • I am very excited to see which previously inaccessible but important scientific and pathobiology questions this innovative NMR technology can address.
  • Dr. Guido Pintacuda, CNRS Research Director and Director of the Lyon High-field NMR Center explained: The new Bruker 160 kHz MAS HCN probe will push structural, cellular and disease biology research into the next phase of the solid-state NMR scientific evolution.

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Retrieved on: 
Monday, July 11, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, University of Barcelona, Solution, Hertz, Bruker, Molecular biology, Cell biology, Internally displaced person, Proteomics, Precision medicine, Metabolomics, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, RIKEN, Intrinsically disordered proteins, CIC, Utrecht University, Maintenance, Multimedia, Ascend, University, EPR, Conference, Research, Life, NMR, Microscopy, Laboratory, Medical imaging, Helium

At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.

Key Points: 
  • At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.
  • The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell biology and pathobiology research.
  • View the full release here: https://www.businesswire.com/news/home/20220711005260/en/
    Compact 1.0 GHz NMR magnet Ascend Evo for structural biology applications and clinical research in single-story laboratories (Graphic: Business Wire)
    A first new 1.0 GHz NMR order comes from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan.
  • Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors

Retrieved on: 
Tuesday, April 12, 2022
Oncogenomics, Board, Spiritual Ambassador program, ALX, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Microdeletion syndrome, U.S. Securities and Exchange Commission, Security (finance), Research, Board of directors, HBA, Doctor of Philosophy, GLOBE, University of Mainz, Patient, FC, SAN, CD47, Bayer, Lymphatic system, SEC, Forward-looking statement, Health care, Organization, University, Acute myeloid leukemia, Cancer, Medical imaging, Biology

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the Board) effective April 11, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the Board) effective April 11, 2022.
  • We are excited to welcome Dr. Canamasas to our Board during an important time in ALX Oncologys continued evolution, said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology.
  • Dr. Canamasas provides a proven track record of successful oncology product launches and transformational strategic expertise to ALX Oncology that will be instrumental in 2022 and beyond as we execute on helping patients fight cancer.
  • I am excited to join the Board at this pivotal junction in ALX Oncologys growth trajectory.

Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Critical Ecosystem Partnership Fund, Oncology, Principal, Teaching hospital, LP, Rockefeller University, Company, UCSF School of Medicine, Bevacizumab, Colon cancer staging, National Cancer Institute, Therapy, Sofinnova, ESMO, Naval Medical Research Unit Six, UCSF, Vall, Programming Development Manager, Wuxi, Translation, UCSF Helen Diller Family Comprehensive Cancer Center, Patient, Colorectal cancer, American Association for Cancer Research, Novo Holdings A/S, United States Air Force Scientific Advisory Board, Clinical Cancer Research, LLC, Program, University, RNA, Pl@ntNet, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, FOLFIRI, III, Annals of Oncology, Rutgers University, Alliance, Pharmaceutical industry

We are honored to welcome Dr. Tabernero and Dr. Venook to our scientific advisory board, commented Masoud Tavazoie, M.D., Ph.D., Chief Executive Officer of Inspirna.

Key Points: 
  • We are honored to welcome Dr. Tabernero and Dr. Venook to our scientific advisory board, commented Masoud Tavazoie, M.D., Ph.D., Chief Executive Officer of Inspirna.
  • Both individuals are experts in their respective fields and have extensive clinical experience in Gastrointestinal oncology and the development of molecular targeted therapies.
  • I am pleased to be joining the Scientific Advisory Board at Inspirna, said Dr. Tabernero.
  • The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers.